Oral Solid Dosage Contract Manufacturing Market Size & Growth Forecast 2027–2036, By Segments (Product, Mechanism, End Use), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Oral Solid Dosage Contract Manufacturing Market size was around USD 11.1 billion in 2026 and is slated to grow at a 9.22% CAGR from 2027 to 2036, exceeding USD 26.81 billion by 2036. The industry revenue for 2027 is estimated at USD 11.96 billion.
Get more details on this report
Request Free Sample ReportOral Solid Dosage Contract Manufacturing Market Intelligence Snapshot
Regional Market Dynamics
- North America leads through its concentration of experienced contract manufacturers, mature outsourcing practices, broad production capabilities, and reliable regulatory and supply infrastructure supporting pharmaceutical companies.
- Asia Pacific is projected to grow at a 6.89% CAGR, supported by cost-efficient manufacturing, expanding pharmaceutical production capacity, and rising outsourcing from multinational and regional drug companies.
Segment Momentum
- Tablets accounted for 34.7% of the market in 2026 due to broad therapeutic use, cost-efficient large-scale production, and suitability for consistent dosing, packaging flexibility, and long-term commercial supply.
- Immediate Release is growing fastest because it supports quicker development timelines and simpler manufacturing, making it an attractive outsourcing option for companies seeking efficient production and product lifecycle management.
Market Expansion Drivers
- Rising pharmaceutical outsourcing accelerating demand for integrated CDMO oral dosage manufacturing services.
- Expanding generic drug launches following patent expirations increasing high-volume tablet production requirements.
- Growing investment in regionalized manufacturing networks strengthening supply chain continuity for oral therapies.
Leading Market Participants
- Leading players in the oral solid dosage contract manufacturing market include Catalent, Inc. (United States), Lonza Group AG (Switzerland), Thermo Fisher Scientific Inc. (United States), Aenova Holding GmbH (Germany), Recipharm AB (Sweden), Siegfried Holding AG (Switzerland), CordenPharma International GmbH (Germany), Piramal Pharma Solutions (India), Jubilant Pharmova Limited (India), NextPharma GmbH (Germany).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 11.1 billion
- 2027 Estimated Market Size: USD 11.96 billion.
- Projected Market Size: USD 26.81 billion by 2036
- Growth Forecast: 9.22% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Tablets (Product) | Controlled Release (Mechanism) | Large Size Companies (End Use)
- Emerging Opportunity Segment: Capsules (Product) | Immediate Release (Mechanism) | Medium & Small Size Companies (End Use)
Market Growth Drivers and Industry Trends
Rising pharmaceutical outsourcing accelerating demand for integrated CDMO oral dosage manufacturing services
Pharmaceutical companies are increasingly outsourcing development and manufacturing activities to external specialists to access technical capabilities, production infrastructure, and flexible capacity without maintaining all operations internally. This trend will drive the oral solid dosage contract manufacturing market as drug developers seek integrated partners capable of supporting formulation development, scale-up, manufacturing, packaging, and related services for oral therapies. Outsourcing also enables pharmaceutical companies to concentrate internal resources on research, commercialization, and portfolio management while relying on specialized manufacturing providers to manage complex production requirements and quality systems.
Expanding generic drug launches following patent expirations increasing high-volume tablet production requirements
Patent expirations create opportunities for generic manufacturers to introduce alternative versions of established medicines, increasing the need for efficient and scalable production of tablets, capsules, and other oral formulations. As generic drug launches expand, the oral solid dosage contract manufacturing market benefits from manufacturers seeking external production partners with suitable equipment, validated processes, and capacity for recurring high-volume orders. Contract manufacturers can support generic drug developers by facilitating production scale-up and maintaining consistent quality across larger manufacturing runs, particularly when demand rises rapidly after market exclusivity ends.
Growing investment in regionalized manufacturing networks strengthening supply chain continuity for oral therapies
Pharmaceutical supply chains are increasingly being structured around geographically diversified manufacturing capabilities to reduce dependence on concentrated production bases and improve resilience during disruptions. Investment in regionalized capacity will strengthen the oral solid dosage contract manufacturing market as pharmaceutical companies seek manufacturing partners located closer to key markets and distribution networks. Regional production arrangements can shorten supply routes, improve responsiveness to changing demand, and provide additional flexibility for companies managing regulatory requirements and product availability across multiple markets, while contract manufacturers expand localized capabilities for oral drug production.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising pharmaceutical outsourcing accelerating demand for integrated CDMO oral dosage manufacturing services | 2.00% | High | North America, Asia Pacific | High | Near Term |
| Expanding generic drug launches following patent expirations increasing high-volume tablet production requirements | 1.80% | Moderate | Asia Pacific, Europe | High | Near Term |
| Growing investment in regionalized manufacturing networks strengthening supply chain continuity for oral therapies | 1.40% | Moderate | North America, Europe | Medium | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
The oral solid dosage contract manufacturing market was led by North America in 2026, supported by a mature pharmaceutical manufacturing ecosystem, established regulatory capabilities, and strong demand for outsourced drug production. Pharmaceutical companies increasingly rely on specialized contract manufacturers to improve production flexibility, manage manufacturing complexity, and access advanced formulation and packaging capabilities. The region's established supply chains, technical expertise, and quality-focused manufacturing environment strengthen its attractiveness for oral solid dosage production. Growing pharmaceutical development activity and increasing emphasis on efficient commercialization are also encouraging the use of external manufacturing partners.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is expected to be the fastest-growing regional market, driven by expanding pharmaceutical manufacturing capacity, competitive production environments, and increasing investment in healthcare infrastructure. Pharmaceutical companies are increasingly using regional manufacturing partners to support formulation, scale-up, and commercial production while improving supply-chain flexibility. Improvements in manufacturing quality systems and regulatory capabilities are making the region increasingly attractive for outsourced drug production. Growing domestic demand for medicines and the expansion of pharmaceutical production capabilities are further creating opportunities for contract manufacturers serving oral solid dosage requirements.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants/Startups i Scale Low Medium High | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Quality-Centric Production HubGermany remains a preferred location for oral solid dosage manufacturing projects that require stringent quality standards and advanced process control. Pharmaceutical companies in Germany are increasingly partnering with contract manufacturers that offer integrated development, scale-up, and commercial production services.
France 🇫🇷
Integrated Development ServicesFrance is increasingly utilizing contract manufacturers that can combine formulation development with commercial oral solid dosage production. Pharmaceutical firms in France are prioritizing partners capable of managing regulatory compliance and flexible manufacturing for diverse therapeutic categories.
Italy 🇮🇹
Generic Drug Manufacturing BaseItaly maintains a strong role in oral solid dosage contract manufacturing through its established generic pharmaceutical sector and export-oriented production facilities. Companies in Italy are investing in production efficiency and packaging integration to serve multinational pharmaceutical clients.
Japan 🇯🇵
Specialized Formulation SupportJapan is emphasizing oral solid dosage contract manufacturing for specialty medicines and age-friendly formulations. Japanese pharmaceutical companies are seeking manufacturing partners with expertise in controlled-release technologies and efficient production methods for smaller, high-value product batches.
South Korea 🇰🇷
Biopharma Diversification PlatformSouth Korea is strengthening its oral solid dosage contract manufacturing capabilities as domestic pharmaceutical companies diversify beyond biologics. Manufacturers in South Korea are investing in modern production lines and export-ready facilities that can support regional and international supply requirements.
United States 🇺🇸
Outsourcing Scale ExpansionThe U.S. market is seeing increased demand for oral solid dosage contract manufacturing from pharmaceutical companies seeking flexible production capacity and supply chain resilience. Contract manufacturers in the U.S. are expanding high-potency and complex formulation capabilities to support both branded and generic drug portfolios.
Segment Leadership and Growth Trends
Oral Solid Dosage Contract Manufacturing Market Share (%), by Product, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportProduct Segment Analysis: Tablets (Largest Segment) vs Capsules (Fastest-Growing Segment)
The tablets segment accounted for the largest share of 34.7% in 2026 in the oral solid dosage contract manufacturing market, supported by its established role as a widely used pharmaceutical dosage form. Tablets offer practical advantages in manufacturing, handling, packaging, and administration, making them suitable for a broad range of drug formulations. Continued outsourcing of pharmaceutical production and the need for scalable, standardized manufacturing capabilities support strong demand for contract manufacturing services focused on tablet production.
Capsules are the fastest-growing product segment as pharmaceutical developers increasingly seek flexible dosage formats that can accommodate different formulations and patient preferences. Capsules can support efficient delivery of active ingredients and provide manufacturers with adaptable options for developing oral therapies. Increasing outsourcing activity and continued innovation in oral drug formulations are creating additional opportunities for contract manufacturers with capsule production capabilities.
Mechanism Segment Analysis: Controlled Release (Largest Segment) vs Immediate Release (Fastest-Growing Segment)
Controlled release held the largest share in 2026 in the oral solid dosage contract manufacturing market, reflecting demand for dosage forms designed to regulate drug release over an extended period. Controlled-release formulations can support more consistent drug exposure and improve dosing convenience, making them valuable for therapies where sustained delivery is important. Growing interest in patient-friendly dosage regimens and advanced formulation strategies continues to support outsourcing demand for controlled-release manufacturing capabilities.
Immediate release is the fastest-growing mechanism segment as pharmaceutical development continues to require dosage forms that provide straightforward and rapid delivery of active ingredients. Immediate-release products remain relevant across a broad range of therapeutic applications and can offer practical formulation and administration characteristics. Continued demand for accessible oral therapies, combined with expanding outsourcing of pharmaceutical production, is supporting greater use of contract manufacturing services for immediate-release formulations.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Product | Tablets, Capsules, Powders, Granules, Others | Tablets | Capsules |
| Mechanism | Immediate Release, Delayed Release, Controlled Release | Controlled Release | Immediate Release |
| End Use | Large Size Companies, Medium & Small Size Companies, Others | Large Size Companies | Medium & Small Size Companies |
Competitive Landscape and Market Positioning
Key companies in the oral solid dosage contract manufacturing market:
1. Catalent Inc. (United States)
2. Lonza Group AG (Switzerland)
3. Thermo Fisher Scientific Inc. (United States)
4. Aenova Holding GmbH (Germany)
5. Recipharm AB (Sweden)
6. Siegfried Holding AG (Switzerland)
7. CordenPharma International GmbH (Germany)
8. Piramal Pharma Solutions (India)
9. Jubilant Pharmova Limited (India)
10. NextPharma GmbH (Germany)
The oral solid dosage contract manufacturing market is evolving through increased outsourcing demand and efficiency-focused production models. Advanced formulation technologies and process optimization are improving scalability and regulatory compliance. Strategic consolidation and innovation efforts are strengthening operational capabilities across the oral solid dosage contract manufacturing market.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Catalent Inc. (United States) | |||||||
| Lonza Group AG (Switzerland) | |||||||
| Thermo Fisher Scientific Inc. (United States) | |||||||
| Aenova Holding GmbH (Germany) | |||||||
| Recipharm AB (Sweden) | |||||||
| Siegfried Holding AG (Switzerland) | |||||||
| CordenPharma International GmbH (Germany) | |||||||
| Piramal Pharma Solutions (India) | |||||||
| Jubilant Pharmova Limited (India) | |||||||
| NextPharma GmbH (Germany). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Forma Life Sciences | Mar-26 | Forma Life Sciences launched a U.S.-based CDMO platform with two GMP-certified facilities focused on oral solid dosage development and manufacturing. The platform integrates clinical-to-commercial scale production capabilities and advanced formulation services, strengthening end-to-end contract manufacturing capacity for oral solid dosage forms across development and commercialization stages. |
| Piramal Pharma Solutions | Apr-25 | Piramal Pharma Solutions launched a dedicated oral solid dosage manufacturing suite in Pennsylvania to support fixed-dose combination therapies. The facility enhances production scalability, operational efficiency, and readiness for high-demand therapeutic programs, reinforcing its contract manufacturing capabilities in oral solid dosage development and commercial supply. |
| Jabil | Feb-25 | Jabil acquired Pharmaceutics International, Inc., expanding its CDMO capabilities in oral solid dosage and drug delivery systems. The acquisition enhances Jabil’s integrated development and commercial manufacturing offering, strengthening its position in pharmaceutical contract manufacturing with broader end-to-end service coverage across oral solid dosage production. |
| Aenova Group | Jul-23 | Aenova Group entered a strategic partnership with Galvita to enhance oral dosage formulation development and production. The collaboration integrates Galvita’s expertise in pediatric and geriatric formulations, including taste masking and fast disintegration technologies, into Aenova’s oral solid dosage portfolio, improving differentiation in patient-centric drug delivery solutions. |
| Aenova Group | Apr-23 | Aenova Group invested approximately USD 21.96 million to expand its high-volume solids manufacturing site in Tittmoning. The expansion increases production capacity for film-coated tablets, conventional oral tablets, and hard capsules, strengthening its large-scale oral solid dosage manufacturing capabilities amid rising global demand. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Oral Solid Dosage Contract Manufacturing Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Therapeutic Area | Oncology, Cardiovascular & Metabolic, Central Nervous System, Infectious Diseases, Other Therapeutic Areas |
| Manufacturing Service | Development & Formulation, Clinical Trial Manufacturing, Commercial Manufacturing, Packaging & Labeling |
| Potency Classification | Non-Potent, Potent, Highly Potent |
Oral Solid Dosage Contract Manufacturing Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| Outsourcing Demand and Client Opportunity Analysis |
|
| CDMO Capacity Expansion Assessment |
|
| Pharmaceutical Supply Chain Resilience Study |
|
Need a different cut of the data?
Request Custom ResearchHow big is the oral solid dosage contract manufacturing market?
What is the anticipated CAGR of the oral solid dosage contract manufacturing industry?
Why are pharmaceutical companies increasingly selecting integrated CDMOs for oral solid dosage manufacturing?
How are regional manufacturing investments influencing outsourcing strategies in the oral solid dosage contract manufacturing market?
Why do tablets hold the largest share in the oral solid dosage contract manufacturing market?
Why is Immediate Release the fastest-growing mechanism in the oral solid dosage contract manufacturing market?
Why does North America dominate the oral solid dosage contract manufacturing market?
What is accelerating growth in the Asia Pacific oral solid dosage contract manufacturing market?
Who are the major participants shaping the oral solid dosage contract manufacturing landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization